Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers

摘要: SUMMARY There is a growing appreciation of the potential value combining novel molecularly-targeted drugs with radiotherapy or chemoradiotherapy. Such approaches have to improve locoregional disease control and cure rates across diverse range tumour types. In this report, we outline rational framework for developing drug–radiation combinations. doing so, make recommendations regarding core preclinical data sets that are required serve as justification studies in humans describe clinical trial designs may be adopted by investigators. Radiotherapy (RT) has pivotal role management many tumours, such B50% cancer patients will receive RT during course their illnesses 40% those cured received part treatment (http://info.cancerresearchuk. org/). Indications prescribing include (i) definitive, curative (radical) treatment; (ii) adjuvant therapy following surgery an attempt eradicate microscopic (or rarely macroscopic) residual disease; (iii) palliative ameliorate cancerrelated symptoms. majority situations, highly localised targets defined volumes tissue known suspected) contain cells. Wide-field hemibody (Bashir et al, 2008) total body (Adkins DiPersio, irradiation techniques used very specific indications, metastatic bone ‘conditioning’ before transplantation haematological malignancies, respectively. addition, latest developments stereotactic (SBRT) also resulted protocols aim treat oligometastatic spread through organ more than